NYX Nyse Euronext

Global Derivatives ADV Down Year-over-Year but Up Sequentially

European and U.S. Cash Equities ADV Down Year-over-Year but Up Sequentially

NYSE Euronext (NYX) today announced trading volumes for its global derivatives and cash equities exchanges for September 20131. Global derivatives average daily volume (“ADV”) of 6.5 million contracts, excluding Bclear in September 2013 decreased 7.5% compared to September 2012, but increased 12.7% from August 2013. U.S. equity options volumes in September 2013 decreased 11.7% compared to September 2012, but increased 8.8% sequentially. ADV in U.S. cash equities declined 9.3% year-over-year, but increased 13.1% month-over-month. European cash equities ADV in September 2013 decreased 5.8% compared to September 2012, but increased 4.8% from August 2013 levels.

Highlights

• NYSE Euronext global derivatives ADV in September 2013 of 6.5 million contracts, excluding Bclear, decreased 7.5% from September 2012, but increased 12.7% from August 2013 levels.
• NYSE Euronext European derivatives products ADV in September 2013 of 2.8 million contracts, excluding Bclear, decreased 1.4% compared to September 2012, but increased 16.4% from August 2013 levels. Including Bclear, NYSE Liffe’s trade administration and clearing service for OTC products, European derivatives ADV decreased 8.4% compared to September 2012, but increased 11.4% from August 2013.
• NYSE Euronext U.S. equity options (NYSE Arca and NYSE Amex Options) ADV of 3.6 million contracts in September 2013 decreased 11.7% compared to September 2012 levels, but increased 8.8% from August 2013 levels. NYSE Euronext’s U.S. options exchanges accounted for 25.5% of total U.S. consolidated equity options trading in September 2013, down from 26.0% in September 2012, but up from 25.3% in August 2013.
• NYSE Liffe U.S. ADV of approximately 73,700 contracts decreased from 83,700 contracts in September 2012, but increased from 31,400 contracts in August 2013.
• NYSE Euronext European cash products ADV of 1.3 million transactions in September 2013 decreased 5.8% compared to September 2012 but, increased 4.8% compared to August 2013.
• NYSE Euronext U.S. cash products (NYSE, NYSE Arca and NYSE MKT) handled ADV of 1.5 billion shares in September 2013 decreased 9.3% compared to September 2012, but increased 13.1% compared to August 2013. NYSE Euronext’s Tape A matched market share in September 2013 was 31.3%, up from 31.1% in September 2012 and up from 30.7% in August 2013.
• The preliminary average net revenue per transaction type (as defined below) for each of the primary trading venues in the third quarter of 2013 is included below:

         

 

            Preliminary Trading Venue     3Q12     2Q13     3Q13 European Derivatives (ex. Bclear)1 $0.657 $0.610 $0.63 U.S. Derivatives2 $0.144 $0.156 $0.16 European Cash3 $0.537 $0.562 $0.54 U.S. Cash4     $0.040     $0.047     $0.048

1 Average net revenue per contract, excluding Bclear.

2 Average net revenue per contract. Excludes NYSE Liffe U.S. trading volume.

3 Average net revenue per transaction.

4 Average net revenue per 100 shares handled.

 

Other Metrics

• The average EUR/USD exchange rate for the third quarter of 2013 of $1.33 represented an increase of 1.5% from the second quarter of 2013 and an increase of 5.8% compared to the third quarter of 2012. The average GBP/USD exchange rate for the third quarter of 2013 of $1.55 represented a decrease of 1.0% from the second quarter of 2013 and a decrease of 1.9% compared to the third quarter of 2012.

Please click here for the Monthly Transaction Activity Data Table.

____________________________

1

 

All NYSE Euronext derivatives transactions count buy and sell orders together as a single transaction. NYSE Euronext European equities transactions count each buy and sell order as separate transactions, NYSE Euronext U.S. equities transactions count buy and sell orders together as a single transaction.

 

About NYSE Euronext

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets - the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca - represent one-third of the world’s equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more information, please visit: http://www.nyx.com.

nyx.com

Please follow us at:Exchanges BlogFacebookLinkedInTwitter

CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS

This written communication contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “may,” “hope,” “will,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential,” “continue,” “could,” “future” or the negative of those terms or other words of similar meaning. You should carefully read forward-looking statements, including statements that contain these words, because they discuss our future expectations or state other “forward-looking” information. Forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. ICE Group, ICE and NYSE Euronext caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement.

Forward-looking statements include, but are not limited to, statements about the benefits of the proposed merger involving ICE Group, ICE and NYSE Euronext, including future financial results, ICE’s and NYSE Euronext’s plans, objectives, expectations and intentions, the expected timing of completion of the transaction and other statements that are not historical facts. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in ICE’s and NYSE Euronext’s filings with the U.S. Securities and Exchange Commission (the “SEC”). These risks and uncertainties include, without limitation, the following: the inability to close the merger in a timely manner; the failure to satisfy other conditions to completion of the merger, including receipt of required regulatory and other approvals; the failure of the proposed transaction to close for any other reason; the possibility that any of the anticipated benefits of the proposed transaction will not be realized; the risk that integration of NYSE Euronext’s operations with those of ICE will be materially delayed or will be more costly or difficult than expected; the challenges of integrating and retaining key employees; the effect of the announcement of the transaction on ICE’s, NYSE Euronext’s or the combined company’s respective business relationships, operating results and business generally; the possibility that the anticipated synergies and cost savings of the merger will not be realized, or will not be realized within the expected time period; the possibility that the merger may be more expensive to complete than anticipated, including as a result of unexpected factors or events; diversion of management’s attention from ongoing business operations and opportunities; general competitive, economic, political and market conditions and fluctuations; actions taken or conditions imposed by the United States and foreign governments or regulatory authorities; and adverse outcomes of pending or threatened litigation or government investigations. In addition, you should carefully consider the risks and uncertainties and other factors that may affect future results of the combined company, as are described in the section entitled “Risk Factors” in the joint proxy statement/prospectus filed by ICE Group with the SEC, and as described in ICE’s and NYSE Euronext’s respective filings with the SEC that are available on the SEC’s web site located at www.sec.gov, including the sections entitled “Risk Factors” in ICE’s Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC on February 6, 2013, and “Risk Factors” in NYSE Euronext’s Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC on February 26, 2013. You should not place undue reliance on forward-looking statements, which speak only as of the date of this written communication. Except for any obligations to disclose material information under the Federal securities laws, ICE Group, ICE and NYSE Euronext undertake no obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this written communication.

IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND WHERE TO FIND IT

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the proposed transaction, ICE Group has filed with the SEC a registration statement on Form S−4, which the SEC has declared effective and which contains a joint proxy statement/prospectus with respect to the proposed acquisition of NYSE Euronext by ICE Group. The final joint proxy statement/prospectus has been delivered to the stockholders of ICE and NYSE Euronext. INVESTORS AND SECURITY HOLDERS OF BOTH ICE AND NYSE EURONEXT ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION CAREFULLY AND IN ITS ENTIRETY, INCLUDING ANY DOCUMENTS PREVIOUSLY FILED WITH THE SEC AND INCORPORATED BY REFERENCE INTO THE JOINT PROXY STATEMENT/PROSPECTUS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE IT CONTAINS IMPORTANT INFORMATION REGARDING ICE, NYSE EURONEXT AND THE PROPOSED TRANSACTION. Investors and security holders may obtain a free copy of the joint proxy statement/prospectus, as well as other filings containing information about ICE and NYSE Euronext, without charge, at the SEC’s website at http://www.sec.gov. Investors may also obtain these documents, without charge, from ICE’s website at http://www.theice.com and from NYSE Euronext’s website at http://www.nyx.com.

NYSE Euronext

Monthly Volume Summary

    Average Daily Volume   Total Volume   Average Daily Volume   Total Volume          

% Chg vs.

 

% Chg vs.

(Unaudited; contracts in thousands) Sep-13 Sep-12 % Chg Sep-13 Sep-12 % Chg YTD 2013

YTD 2012

YTD 2013

YTD 2012

  Number of Trading Days - European Cash 21 20 21 20 191 191 Number of Trading Days - European Derivatives 21 20 21 20 192 192 Number of Trading Days - U.S. Markets 20 19 20 19 188 188   European Derivatives Products 3,164 3,455 -8.4% 66,435 69,105 -3.9% 3,882 2.7% 745,379 2.2% of which Bclear 333 584 -43.1% 6,986 11,685 -40.2% 688 -36.0% 132,099 -36.3%   Total Fixed Income Products 2,033 1,998 1.8% 42,700 39,965 6.8% 2,385 31.2% 457,895 30.5%   Short Term Interest Rate Products 1,884 1,841 2.3% 39,567 36,828 7.4% 2,207 32.4% 423,839 31.7%

Medium and Long Term Interest Rate Products 1

149 157 -4.9% 3,134 3,138 -0.1% 177 17.7% 34,056 17.1%  

Total Equity Products 2

1,037 1,363 -23.9% 21,780 27,261 -20.1% 1,405 -25.1% 269,845 -25.4%   Individual Equity Products 522 814 -36.0% 10,952 16,288 -32.8% 907 -34.7% 174,114 -35.0% Futures 127 395 -67.9% 2,658 7,895 -66.3% 513 -44.8% 98,557 -45.1% Options 395 420 -5.9% 8,294 8,393 -1.2% 394 -14.1% 75,557 -14.6% Equity Index Products 516 549 -6.0% 10,828 10,972 -1.3% 499 2.2% 95,731 1.7%   of which Bclear 331 584 -43.4% 6,950 11,685 -40.5% 687 -36.1% 131,846 -36.4% Individual Equity Products 220 456 -51.6% 4,629 9,118 -49.2% 587 -41.3% 112,792 -41.6% Futures 122 382 -68.2% 2,558 7,650 -66.6% 500 -44.7% 96,001 -45.0% Options 99 73 34.3% 2,071 1,469 41.0% 87 -8.8% 16,791 -9.3% Equity Index Products 111 128 -13.9% 2,321 2,567 -9.6% 99 33.2% 19,054 32.5%   Commodity Products 93 94 -0.9% 1,955 1,879 4.0% 92 5.8% 17,639 5.2%   U.S. Derivatives Products  

Equity Options 3

  NYSE Euronext Options Contracts 3,641 4,122 -11.7% 72,828 78,318 -7.0% 4,036 4.6% 758,723 4.6% Total Consolidated Options Contracts 14,292 15,863 -9.9% 285,832 301,402 -5.2% 14,826 -0.2% 2,787,252 -0.2%   NYSE Group Share of Total 25.5% 26.0% 25.5% 26.0% 27.2% 1.2% 27.2% 1.2%   NYSE Liffe U.S.   Futures and Futures Options Volume* 73.7 83.7 -11.9% 1,548 1,673 -7.5% 55.9 -28.9% 10,796.0 -28.9%   European Cash Products (trades in thousands) 1,343 1,426 -5.8% 28,206 28,530 -1.1% 1,395 -9.1% 266,371 -9.6%   Equities 1,300 1,377 -5.6% 27,292 27,533 -0.9% 1,346 -9.3% 257,036 -9.8% Exchange-Traded Funds 13 14 -7.3% 267 274 -2.7% 14 -0.8% 2,616 -1.3% Structured Products 27 30 -12.3% 559 607 -7.9% 30 -4.6% 5,810 -5.1% Bonds 4 6 -27.4% 88 116 -23.8% 5 -6.2% 910 -6.7%  

U.S. Cash Products (shares in millions) 5

1,514 1,669 -9.3% 30,286 31,720 -4.5% 1,528 -11.7% 287,177 -11.7%   NYSE Listed (Tape A) Issues 4   Handled Volume 5 1,085 1,218 -11.0% 21,693 23,146 -6.3% 1,092 -11.7% 205,310 -11.7% Matched Volume 6 1,051 1,160 -9.4% 21,021 22,034 -4.6% 1,053 -10.2% 197,956 -10.2% Total NYSE Listed Consolidated Volume 3,361 3,730 -9.9% 67,212 70,866 -5.2% 3,442 -8.0% 647,161 -8.0%   Share of Total Consolidated Volume Handled Volume 5 32.3% 32.7% -0.4% 32.3% 32.7% -0.4% 31.7% -1.3% 31.7% -1.3% Matched Volume 6 31.3% 31.1% 0.2% 31.3% 31.1% 0.2% 30.6% -0.8% 30.6% -0.8%   NYSE Arca, MKT and Regional (Tape B) Listed Issues   Handled Volume 5 262 241 8.8% 5,248 4,583 14.5% 251 -1.7% 47,194 -1.7% Matched Volume 6 243 219 11.1% 4,868 4,161 17.0% 231 0.6% 43,514 0.6% Total NYSE Arca & MKT Listed Consolidated Volume 1,067 1,048 1.7% 21,331 19,919 7.1% 1,091 0.8% 205,192 0.8%   Share of Total Consolidated Volume Handled Volume 5 24.6% 23.0% 1.6% 24.6% 23.0% 1.6% 23.0% -0.6% 23.0% -0.6% Matched Volume 6 22.8% 20.9% 1.9% 22.8% 20.9% 1.9% 21.2% 0.0% 21.2% 0.0%   Nasdaq Listed (Tape C) Issues   Handled Volume 5 167 210 -20.4% 3,345 3,991 -16.2% 184 -22.1% 34,673 -22.1% Matched Volume 6 148 181 -18.5% 2,955 3,443 -14.2% 165 -18.7% 30,946 -18.7% Total Nasdaq Listed Consolidated Volume 1,764 1,796 -1.8% 35,271 34,117 3.4% 1,743 -0.6% 327,665 -0.6%   Share of Total Consolidated Volume Handled Volume 5 9.5% 11.7% -2.2% 9.5% 11.7% -2.2% 10.6% -2.9% 10.6% -2.9% Matched Volume 6 8.4% 10.1% -1.7% 8.4% 10.1% -1.7% 9.4% -2.2% 9.4% -2.2%   Exchange-Traded Products 5,7   Handled Volume 5 239 220 8.4% 4,771 4,181 14.1% 235 -2.0% 44,093 -2.0% Matched Volume 6 221 200 10.6% 4,421 3,796 16.4% 216 0.5% 40,645 0.5% Total ETF Consolidated Volume 997 987 1.0% 19,944 18,758 6.3% 1,044 -0.2% 196,288 -0.2%   Share of Total Consolidated Volume Handled Volume 5 23.9% 22.3% 1.6% 23.9% 22.3% 1.6% 22.5% -0.4% 22.5% -0.4% Matched Volume 6 22.2% 20.2% 2.0% 22.2% 20.2% 2.0% 20.7% 0.1% 20.7% 0.1% 1   Data includes currency products.

2

Includes all trading activities for Bclear, NYSE Liffe's clearing service for wholesale derivatives. 3 Includes trading in U.S. equity options contracts, not equity-index options. 4 Includes all volume executed in NYSE Group crossing sessions. 5 Represents the total number of shares of equity securities and ETFs internally matched on the NYSE Group's exchanges or routed to and executed at an external market center. NYSE Arca routing includes odd-lots. 6 Represents the total number of shares of equity securities and ETFs executed on the NYSE Group's exchanges. 7 Data included in previously identified categories. * ADVs calculated with the appropriate number of NYSE Liffe U.S. trading days. Source: NYSE Euronext, Options Clearing Corporation and Consolidated Tape as reported for equity securities. All trading activity is single-counted, except European cash trading which is double counted to include both buys and sells.

NYSE EuronextMedia:Amsterdam, +31-20-550-4488Lisbon, +351-217-900-029New York, +1-212-656-2411Brussels, +32-2-509-1392London, +44-20-7379-2789Paris, +33-1-49-27-11-33orInvestor Relations:New York, +1-212-656-5700